Big Moment Looks Overdone: Collegium Pharmaceutical, Inc. (NASDAQ: COLL)

On 14 Jan 2020, Collegium Pharmaceutical, Inc. (NASDAQ: COLL) spotted trading -2.14% off 52-week high price. On the other end, the stock has been noted 135.41% away from the low price over the last 52-weeks. The stock changed -1.77% to recent value of $23.57. The stock transacted 435259 shares during most recent day however it has an average volume of 449.26K shares.

Collegium Pharmaceutical, Inc. (COLL) recently stated its financial results for the quarter ended September 30, 2019 and provided a corporate update.

Financial Results for Quarter Ended September 30, 2019

Xtampza ER net product revenues were $26.5M for the quarter ended September 30, 2019 (the “2019 Quarter”), contrast to $17.0M for the quarter ended September 30, 2018 (the “2018 Quarter”) and $26.0M for the quarter ended June 30, 2019, representing a raise of 56% and 2%, respectively.

Nucynta franchise net product revenues were $46.4M in the 2019 Quarter, contrast to $53.1M for the 2018 Quarter and $49.0M for the quarter ended June 30, 2019, representing a decrease of 13% and 5%, respectively.

Selling, general and administrative expenses were $30.1M for the 2019 Quarter, contrast to $33.4M for the 2018 Quarter.

Net loss for the 2019 Quarter was $6.1M, or $0.18 per share (basic and diluted), contrast to net loss of $16.5M, or $0.50 per share (basic and diluted), for the 2018 Quarter. Net loss included stock-based compensation expense of $4.1M and $3.9M for the 2019 Quarter and 2018 Quarter, respectively.

Non-GAAP adjusted income for the 2019 Quarter was $1.7M, contrast to a non-GAAP adjusted loss of $8.3M for the 2018 Quarter.

Collegium had cash and cash equivalents of $153.8M as of September 30, 2019, a raise of $5.1M contrast to the second quarter of 2019. The increase in cash and cash equivalents was primarily the result of cash provided by operating activities, partially offset by capital expenditures related to the buildout of additional manufacturing capacity.

Its earnings per share (EPS) expected to touch remained 52.00% for this year while earning per share for the next 5-years is expected to reach at 0.55%. COLL has a gross margin of 41.10% and an operating margin of -3.50% while its profit margin remained -3.90% for the last 12 months. According to the most recent quarter its current ratio was 1.2 that represents company’s ability to meet its current financial obligations. The price moved ahead of 12.71% from the mean of 20 days, 19.80% from mean of 50 days SMA and performed 66.53% from mean of 200 days price. Company’s performance for the week was 18.24%, 13.79% for month and YTD performance remained 14.50%.

 

Leave a comment

(*) Required, Your email will not be published